Literature DB >> 8699151

Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585.

G J Hickey1, J Drisko, T Faidley, C Chang, L L Anderson, S Nicolich, L McGuire, E Rickes, D Krupa, W Feeney, B Friscino, P Cunningham, E Frazier, H Chen, P Laroque, R G Smith.   

Abstract

To investigate the effect of hypophyseal transection (HST) on GH secretagogue activity of the non-peptidyl GH secretagogue L-692,585 in the conscious pig, male castrated swine were randomly assigned to either a hypophyseal stalk transection group (HST; n = 3) or to a sham-operated control group (SOC; n = 3). Treatments administered were L-692,585 (100 micrograms/kg), human GH-releasing factor(1-29)NH2 (GRF; 20 micrograms/kg) or L-692,585 (100 micrograms/kg) + GRF (20 micrograms/kg) on days -7 to -3 before surgery and days +3 to +8 after surgery. To evaluate the integrity of the pituitary gland, the animals were challenged with corticotropin-releasing hormone (CRH; 150 micrograms) or GnRH (150 ng/kg) both before and after surgery. Blood was collected from -60 to +180 min post treatment and assayed for GH, cortisol and LH. Before surgery, no significant difference (P > 0.05) in peak GH response (ng/ml) was present between the two groups (SOC vs HST) in response to L-692,585 (101 +/- 12 vs 71 +/- 9) or L-692,585 + GRF (171 +/- 21 vs 174 +/- 21). Only two out of three SOC vs three out of three HST pigs responded to GRF (13 +/- 2 vs 25 +/- 3) resulting in a significant difference between groups. Following surgery, significant differences were present in peak GH response (ng/ml) between SOC and HST groups following L-692,585 (79 +/- 6 vs 13.8 +/- 1.0); however, the response to L-692,585 + GRF was similar (115 +/- 8 vs 94 +/- 7). All animals responded to GRF; however, a significant difference was present between groups due to the magnitude of the responses. Whereas the cortisol responses (ng/ml) to L-692,585 in the SOC and HST groups were similar before surgery, a significant difference was present after surgery (44.4 +/- 6.4 vs 14.6 +/- 2.1). No significant difference was noted between the HST and SOC groups in response to CRH or GnRH either before or after surgery. These results indicated that L-692,585 induced an immediate GH response in the intact animal in contrast to GRF where the GH release was variable. L-692,585 also stimulated an immediate increase in cortisol levels. Transection of the hypophyseal stalk dramatically decreased but did not ablate the GH or cortisol response to L-692,585. Co-administration of L-692,585 + GRF induced an immediate GH response of similar magnitude in the intact and HST animal. We conclude that L-692,585 has a direct but limited action at the level of the pituitary and that an intact hypophyseal stalk is required for a maximal GH and cortisol response. L-692,585 acts with GRF at the level of the pituitary to induce a maximal GH response. These findings suggest that L-692,585 stimulates GH secretion by acting in combination with GRF and interrupting the inhibitory tone of somatostatin on the somatotroph.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699151     DOI: 10.1677/joe.0.1480371

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  15 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

Review 2.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Synthetic growth hormone secretagogues control growth hormone secretion in the chicken at pituitary and hypothalamic levels.

Authors:  K L Geris; G J Hickey; A Vanderghote; E R Kühn; V M Darras
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.

Authors:  E Arvat; J Ramunni; R Giordano; B Maccagno; F Broglio; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

5.  Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

Authors:  E Arvat; L Di Vito; F Lanfranco; F Broglio; R Giordano; A Benso; G P Muccioli; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

6.  GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Authors:  M R A Martins; A C A R Pinto; E Brunner; M R D Silva; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

7.  Ghrelin stimulation of growth hormone-releasing hormone neurons is direct in the arcuate nucleus.

Authors:  Guillaume Osterstock; Pauline Escobar; Violeta Mitutsova; Laurie-Anne Gouty-Colomer; Pierre Fontanaud; François Molino; Jean-Alain Fehrentz; Danielle Carmignac; Jean Martinez; Nathalie C Guerineau; Iain C A F Robinson; Patrice Mollard; Pierre-François Méry
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

8.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

9.  Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.

Authors:  Sergio Oliva Nascif; Patrícia Molica; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2009-04-26       Impact factor: 4.107

10.  Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.

Authors:  E Arvat; B Maccagno; J Ramunni; F Broglio; F Lanfranco; R Giordano; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.